RBC Life Sciences RBCL Stock
RBC Life Sciences Price Chart
RBC Life Sciences RBCL Financial and Trading Overview
RBC Life Sciences stock price | 0.0001 USD |
Previous Close | 0.0003 USD |
Open | 0.0003 USD |
Bid | 0 USD x 0 |
Ask | 0 USD x 0 |
Day's Range | 0.0003 - 0.0003 USD |
52 Week Range | 0.0003 - 0.01 USD |
Volume | 100 USD |
Avg. Volume | 1 USD |
Market Cap | 126.14K USD |
Beta (5Y Monthly) | -10.360915 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
RBCL Valuation Measures
Enterprise Value | -2090786 USD |
Trailing P/E | N/A |
Forward P/E | 0.00014084506 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.005230645 |
Price/Book (mrq) | 8.255366E-5 |
Enterprise Value/Revenue | -0.087 |
Enterprise Value/EBITDA | 1.165 |
Trading Information
RBC Life Sciences Stock Price History
Beta (5Y Monthly) | -10.360915 |
52-Week Change | -39.99% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.01 USD |
52 Week Low | 0.0003 USD |
50-Day Moving Average | 0.01 USD |
200-Day Moving Average | 0.01 USD |
RBCL Share Statistics
Avg. Volume (3 month) | 1 USD |
Avg. Daily Volume (10-Days) | 10 USD |
Shares Outstanding | 2.21M |
Float | N/A |
Short Ratio | N/A |
% Held by Insiders | 8.31% |
% Held by Institutions | 0% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 50:500 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2014 |
Most Recent Quarter (mrq) | September 30, 2015 |
Next Fiscal Year End | December 31, 2015 |
Profitability
Profit Margin | -2.31% |
Operating Margin (ttm) | -9.59% |
Gross Margin | 56.90% |
EBITDA Margin | -7.43% |
Management Effectiveness
Return on Assets (ttm) | -10.035% |
Return on Equity (ttm) | -6.77% |
Income Statement
Revenue (ttm) | 24.12M USD |
Revenue Per Share (ttm) | 10.9 USD |
Quarterly Revenue Growth (yoy) | -28.10% |
Gross Profit (ttm) | 15.64M USD |
EBITDA | -1794131 USD |
Net Income Avi to Common (ttm) | -559508 USD |
Diluted EPS (ttm) | 0 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 2.09M USD |
Total Cash Per Share (mrq) | 0.95 USD |
Total Debt (mrq) | 0 USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 2.16 |
Book Value Per Share (mrq) | 3.634 |
Cash Flow Statement
Operating Cash Flow (ttm) | -2903004 USD |
Levered Free Cash Flow (ttm) | -2585901 USD |
Profile of RBC Life Sciences
Country | United States |
State | TX |
City | Irving |
Address | 2301 Crown Court |
ZIP | 75038 |
Phone | 972 893 4000 |
Website | https://www.rbclifesciences.com |
Industry | Household & Personal Products |
Sector(s) | Consumer Defensive |
Full Time Employees | 89 |
RBC Life Sciences, Inc. manufactures, markets, and distributes nutritional supplements and personal care products in North America, Southeast Asia, and Australia. The company's Nutritional Products segment offers nutritional supplements and personal care products, including herbs, vitamins, and minerals; and natural skin, hair, and body care products through a network of independent distributors and license arrangements. Its products include Stem-Kine, a dietary supplement; Microhydrin and Microhydrin Plus antioxidants; VitAloe, a blend of research-backed ingredients; OliViva, an antioxidant beverage to support immune and cardiovascular system; Organic Spirulina, a nutritious alga that provides range of nutrients and easily digested proteins; and NeuroBright to support brain function, and enhance energy and acuity. This segments products also comprise Colo-Vada Plus, a colon cleansing program; HydraCel to enhance the quality of drinking water; 24 Seven, a multivitamin/mineral supplement; Immune 360 to nourish and support the function of the immune system; and Aloe Gelee gel that provides the soothing and moisturizing. Its Medical Products segment offers wound care products for the treatment and healing of wounds, such as pressure ulcers, leg ulcers, cuts, burns, and abrasions. Its products include cleansers, dressings, hydrogels, collagen, calcium alginates, moisture barriers, antimicrobials, and a hydrogel wound dressing with Lidocaine. This segment also offers other wound care products designed to reduce destruction to skin and tissue caused by radiation; and to reduce pain and itching in the skin, and the internal mucosa caused by radiation reactions or reactions to various cancer medications. This segment sells its products under the MPM Medical brand to hospitals, nursing homes, clinics, and pharmacies through a network of medical/surgical supply dealers and pharmaceutical distributors. The company was founded in 1988 and is headquartered in Irving, Texas.
Q&A For RBC Life Sciences Stock
What is a current RBCL stock price?
RBC Life Sciences RBCL stock price today per share is 0.0001 USD.
How to purchase RBC Life Sciences stock?
You can buy RBCL shares on the OTC Markets EXMKT exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for RBC Life Sciences?
The stock symbol or ticker of RBC Life Sciences is RBCL.
Which industry does the RBC Life Sciences company belong to?
The RBC Life Sciences industry is Household & Personal Products.
How many shares does RBC Life Sciences have in circulation?
The max supply of RBC Life Sciences shares is 1.33B.
What is RBC Life Sciences Price to Earnings Ratio (PE Ratio)?
RBC Life Sciences PE Ratio is now.
What was RBC Life Sciences earnings per share over the trailing 12 months (TTM)?
RBC Life Sciences EPS is 0 USD over the trailing 12 months.
Which sector does the RBC Life Sciences company belong to?
The RBC Life Sciences sector is Consumer Defensive.